Can a Needle-Free prostate treatment match implant surgery?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants must satisfy ALL of the following: * Male, aged ≥ 50 and ≤ 80 years * Moderate-to-severe LUTS due to BPH: IPSS total score ≥ 13 at screening * Peak urinary flow rate (Qmax) ≥ 5 and ≤ 12 mL/s with minimum voided volume ≥ 125 mL on free uroflowmetry. The lower Qmax bound of ≥ 5 mL/s excludes near-complete retention with likely detrusor underactivity, as adopted in the Rezūm pivotal trial * Prostate volume 30-80 g by transrectal ultrasound (TRUS) or multiparametric MRI, consistent with the L.I.F.T. and Rezūm pivotal study ranges * Post-void residual (PVR) ≤ 250 mL by bladder ultrasound * Currently on, or has previously tried, medical therapy for BPH (alpha-blocker and/or 5-alpha-reductase inhibitor) for ≥ 4 weeks with inadequate symptom control, or documented intolerance to medical therapy * Able to provide written informed consent * Able and willing to attend all study follow-up visits Exclusion Criteria: Participants will be excluded if ANY of the following apply: * Intravesical prostatic protrusion \> 10 mm on TRUS. * Presence of metallic pelvic implants, penile prosthesis, femoral metallic implant, cardiac pacemaker, or implantable cardioverter-defibrillator. * Previous transurethral resection of the prostate (TURP), HoLEP, or any prior endoscopic prostate surgery. * Prior pelvic radiation therapy. * Prostatic urethral length \< 1.2 cm or \> 5.5 cm. * Confirmed or suspected prostate carcinoma (unresolved elevated PSA without negative biopsy, or any known malignancy). * Active urinary tract infection at screening. * Bladder stone, bladder tumour, or suspected bladder malignancy. * Urethral stricture or bladder neck contracture precluding catheter passage (Foley ≥ 18 Fr). * Neurogenic bladder or known clinically significant detrusor underactivity. * History of acute urinary retention. * Coagulopathy or therapeutic anticoagulation that cannot be bridged perioperatively. * Renal impairment: eGFR \< 30 mL/min/1.73 m² (Cockcroft-Gault). * Desire to preserve fertility (due to risk of retrograde ejaculation with either device). * IPSS QoL bother score \< 3 (patient not sufficiently bothered to warrant procedural intervention). * Participation in another interventional clinical trial within the preceding 30 days.